Parkinson's disease (PD) is a chronic, progressive neurodegenerative disorder that affects movement, muscle control, and balance. It is part of a group of conditions known as motor system disorders, which are the result of the loss of dopamine-producing brain cells.
The exact cause of PD is unknown, but it is thought to involve both genetic and environmental factors. Pathologically, PD is characterized by the degeneration of dopaminergic neurons in the substantia nigra pars compacta and the presence of Lewy bodies, which are protein aggregates that develop inside nerve cells.
PD typically presents with motor symptoms such as bradykinesia, rigidity, tremor, and postural instability. However, non-motor symptoms like autonomic dysfunction, cognitive impairment, and mood disorders can also occur and significantly impact the quality of life.
Diagnosis of PD is primarily clinical, based on the presence of characteristic motor symptoms and the response to dopaminergic therapy. Neuroimaging can be used to rule out other conditions but is not typically required for diagnosis.
Treatment for PD is symptomatic, aiming to improve the quality of life by controlling symptoms. Pharmacological treatment primarily involves the use of dopaminergic medications. Non-pharmacological interventions, such as physical therapy and occupational therapy, are also crucial components of management.
PD is a progressive disease with no cure. The rate of progression varies widely among individuals. While PD itself is not fatal, complications can be serious and include falls, choking, and pneumonia.
Understanding Parkinson's disease involves a comprehensive approach, taking into account its complex pathophysiology, diverse clinical presentation, and the importance of a multidisciplinary approach to treatment. Continued research into the underlying mechanisms and potential treatments is crucial for improving the lives of those affected by this challenging condition.
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation